S&P assigns ‘AA-‘ rating to Nebraska Medicine’s bonds

S&P Global Ratings has assigned an “AA-” rating to Omaha-based Nebraska Medicine’s $130.7 million of series 2016 bonds and $136.4 million of series 2016 bonds.

Advertisement

“The ‘AA-‘ rating reflects our view of such factors as Nebraska Medicine’s position as the premier academic medical center in the growing Omaha service area, strong operating margins, very good coverage and stable balance sheet,” said S&P analyst Kevin Holloran.

The outlook is stable, reflecting S&P’s view of Nebraska Medicine’s strong credit fundamentals, solid business position and strengthening financial profile.

More articles on healthcare finance:
Senator asks CMS to delay ending Medicare payments for Ozarks Community Hospital
Bay Area Hospitalist Associates adopts Salar software to enhance charge capture
Hospitals’ 3 biggest revenue cycle mistakes

Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit

Advertisement

Next Up in Financial Management

Advertisement

Comments are closed.